000756 新华制药
已收盘 03-16 15:00:00
资讯
新帖
简况
新华制药最新公告：获得依折麦布片上市许可持有人变更批准
证券之星 · 03-16 18:00
新华制药最新公告：获得依折麦布片上市许可持有人变更批准
新华制药依折麦布片变更上市许可持有人获批准
美股速递 · 03-16 17:37
新华制药依折麦布片变更上市许可持有人获批准
新华制药：公司构建创新药+特色原料药+高端制剂+CDMO立体布局
证券日报 · 03-09
新华制药：公司构建创新药+特色原料药+高端制剂+CDMO立体布局
新华制药(000756.SZ)子公司获沙格列汀二甲双胍缓释片药品注册证书
智通财经 · 03-04
新华制药(000756.SZ)子公司获沙格列汀二甲双胍缓释片药品注册证书
新华制药(000756.SZ)获恩他卡朋片药品注册证
智通财经 · 03-04
新华制药(000756.SZ)获恩他卡朋片药品注册证
新华制药沙格列汀与盐酸二甲双胍缓释片获批药品注册证书
美股速递 · 03-04
新华制药沙格列汀与盐酸二甲双胍缓释片获批药品注册证书
新华制药：硫酸氨基葡萄糖胶囊获得药品注册证书
南方财经网 · 02-09
新华制药：硫酸氨基葡萄糖胶囊获得药品注册证书
新华制药硫酸氨基葡萄糖胶囊混悬剂获国家药监局药品注册证书
美股速递 · 02-09
新华制药硫酸氨基葡萄糖胶囊混悬剂获国家药监局药品注册证书
历时14个月未谈拢，新华制药终止挪亚圣诺（太仓）股权收购意向
财中社 · 02-06
历时14个月未谈拢，新华制药终止挪亚圣诺（太仓）股权收购意向
新华制药与Novosana终止股权收购意向协议
美股速递 · 02-06
新华制药与Novosana终止股权收购意向协议
新华制药：新华制药是全球解热镇痛类药物重要生产企业
证券之星 · 02-03
新华制药：新华制药是全球解热镇痛类药物重要生产企业
新华制药：布洛芬主要用于解热、镇痛、抗炎，是非甾体抗炎常用药
证券日报网 · 01-27
新华制药：布洛芬主要用于解热、镇痛、抗炎，是非甾体抗炎常用药
新华制药（000756）披露部分A股股票期权注销完成公告，1月20日股价上涨1.54%
证券之星 · 01-20
新华制药（000756）披露部分A股股票期权注销完成公告，1月20日股价上涨1.54%
新华制药调整2021年股权激励计划，行权价格下调并注销部分期权
中金财经 · 01-05
新华制药调整2021年股权激励计划，行权价格下调并注销部分期权
每周股票复盘：新华制药（000756）获间苯三酚注射液注册证
证券之星 · 01-03
每周股票复盘：新华制药（000756）获间苯三酚注射液注册证
流感疫情持续，防控系统工程再受考验
证券之星 · 2025-12-31
流感疫情持续，防控系统工程再受考验
新华制药缬沙坦胶囊获药品注册证书，丰富心血管产品线
中金财经 · 2025-12-30
新华制药缬沙坦胶囊获药品注册证书，丰富心血管产品线
新华制药间苯三酚注射液获药品注册证书，有望开拓新市场
中金财经 · 2025-12-30
新华制药间苯三酚注射液获药品注册证书，有望开拓新市场
发力止痛市场，新华制药间苯三酚注射液获批注册
财中社 · 2025-12-29
发力止痛市场，新华制药间苯三酚注射液获批注册
新华制药：获得缬沙坦胶囊、间苯三酚注射液药品注册证书
人民财讯 · 2025-12-29
新华制药：获得缬沙坦胶囊、间苯三酚注射液药品注册证书
暂无数据
公司概况
公司名称：
山东新华制药股份有限公司
所属行业：
医药制造业
上市日期：
1997-08-06
主营业务：
山东新华制药股份有限公司的主营业务是开发、制造和销售化学原料药、制剂及化工产品。公司的主要产品是“新华牌”解热镇痛类药物、心脑血管类、抗感染类及中枢神经类等药物。1个项目获山东省2024年度科技进步二等奖。
发行价格：
3.45
{"stockData":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":15.37,"timestamp":1773644595000,"preClose":15.35,"halted":0,"volume":3520000,"delay":0,"changeRate":0.0013,"floatShares":499000000,"shares":697000000,"eps":0.5486,"marketStatus":"已收盘","change":0.02,"latestTime":"03-16 15:00:00","open":15.33,"high":15.42,"low":15.3,"amount":54018900,"amplitude":0.0078,"askPrice":15.38,"askSize":249,"bidPrice":15.37,"bidSize":140,"shortable":0,"etf":0,"ttmEps":0.5486,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773711000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.35,"symbolType":"stock","openAndCloseTimeList":[[1773624600000,1773631800000],[1773637200000,1773644400000]],"highLimit":16.89,"lowLimit":13.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":696683435,"isCdr":false,"pbRate":2.08,"roa":"--","peRate":28.01677,"roe":"5.01%","epsLYR":0.69,"committee":-0.394068,"marketValue":10708000000,"turnoverRate":0.0071,"status":0,"hkstockBrief":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":6.72,"timestamp":1773648502002,"preClose":6.69,"halted":0,"volume":512000,"delay":0,"premium":"-61.51"},"floatMarketCap":7668000000},"requestUrl":"/m/hq/s/000756/tweets","defaultTab":"tweets","newsList":[{"id":"2619518024","title":"新华制药最新公告：获得依折麦布片上市许可持有人变更批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619518024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619518024?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:00","pubTimestamp":1773655203,"startTime":"0","endTime":"0","summary":"新华制药(000756.SZ)公告称，公司收到国家药品监督管理局核准签发的依折麦布片《药品补充申请批准通知书》，批准本品上市许可持有人转让补充申请。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600026281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"1164703743","title":"新华制药依折麦布片变更上市许可持有人获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1164703743","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164703743?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:37","pubTimestamp":1773653830,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司近日宣布，其生产的依折麦布片变更上市许可持有人的申请已获得相关监管部门的批准。此次变更将有助于公司优化产品管理结构，提升市场运营效率。依折麦布片作为一种重要的降血脂药物，其上市许可持有人的变更不会影响产品的质量和市场供应，公司将继续确保该药品的安全性和有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2618259096","title":"新华制药：公司构建创新药+特色原料药+高端制剂+CDMO立体布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2618259096","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618259096?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:10","pubTimestamp":1773058240,"startTime":"0","endTime":"0","summary":"证券日报网讯3月9日，新华制药在互动平台回答投资者提问时表示，公司以大研发+全产业链+国际化为核心，构建创新药+特色原料药+高端制剂+CDMO的立体布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666266727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CDMO","BK1574","BK4139","159992","06978","BK1161","000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2616389205","title":"新华制药(000756.SZ)子公司获沙格列汀二甲双胍缓释片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616389205","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616389205?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:56","pubTimestamp":1772614570,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司全资子公司山东淄博新达制药有限公司(简称“新达制药”)收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)、(Ⅲ)《药品注册证书》。本品配合饮食和运动治疗，适合使用沙格列汀和二甲双胍治疗的2型糖尿病成人患者，以改善此类患者的血糖控制。本品不用于1型糖尿病或糖尿病酮症酸中毒的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2616953896","title":"新华制药(000756.SZ)获恩他卡朋片药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616953896","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616953896?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:49","pubTimestamp":1772614182,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公告收到国家药品监督管理局核准签发的恩他卡朋片《药品注册证书》。本品可作为标准药物左旋多巴/苄丝肼或左旋多巴/卡比多巴的辅助用药，用于治疗以上药物不能控制的帕金森病及剂末现象(症状波动)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)获恩他卡朋片药品注册证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"1190496711","title":"新华制药沙格列汀与盐酸二甲双胍缓释片获批药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1190496711","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190496711?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:31","pubTimestamp":1772613076,"startTime":"0","endTime":"0","summary":"新华制药（股票代码：000756）宣布，其研发的沙格列汀与盐酸二甲双胍缓释片正式获得国家药品监督管理局颁发的药品注册证书。该药物主要用于2型糖尿病患者的血糖控制，结合了DPP-4抑制剂与双胍类药物的协同降糖机制。\n此次获批标志着公司在内分泌代谢疾病治疗领域取得重要突破。缓释剂型可减少患者服药频率，提升用药依从性，为糖尿病治疗提供更优选择。随着国内糖尿病患病率持续上升，该产品有望进一步丰富新华制药的代谢类药品管线，增强市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2610663896","title":"新华制药：硫酸氨基葡萄糖胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2610663896","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610663896?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:54","pubTimestamp":1770627297,"startTime":"0","endTime":"0","summary":"南财智讯2月9日电，新华制药公告，公司收到国家药品监督管理局签发的硫酸氨基葡萄糖胶囊《药品注册证书》。该产品用于治疗原发性及继发性骨关节炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602093645467176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"1162349391","title":"新华制药硫酸氨基葡萄糖胶囊混悬剂获国家药监局药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1162349391","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162349391?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:34","pubTimestamp":1770626066,"startTime":"0","endTime":"0","summary":"新华制药（000756）宣布，其研发的硫酸氨基葡萄糖胶囊混悬剂已正式获得国家药品监督管理局（NMPA）颁发的药品注册证书。该药品注册证书的取得，标志着公司该产品已获准在中国市场生产销售，有望进一步丰富公司产品线，并对未来业绩产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2609568560","title":"历时14个月未谈拢，新华制药终止挪亚圣诺（太仓）股权收购意向","url":"https://stock-news.laohu8.com/highlight/detail?id=2609568560","media":"财中社","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609568560?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:35","pubTimestamp":1770377715,"startTime":"0","endTime":"0","summary":"2月6日，新华制药（000756/00719）发布公告，2024年10月，公司披露拟受让NovoSana（Europe）B.V.持有的挪亚圣诺（太仓）生物科技有限公司不超过75%股权。收购完成后，公司将成为挪亚圣诺的控股股东，目标公司将纳入本公司合并报表范围。基于双方没有达成一致意见，根据协议终止条款，意向协议终止，其所涉及的所有条款均终止履行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602063644262750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"1133227148","title":"新华制药与Novosana终止股权收购意向协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1133227148","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133227148?lang=zh_cn&edition=full","pubTime":"2026-02-06 17:55","pubTimestamp":1770371724,"startTime":"0","endTime":"0","summary":"新华制药宣布，公司与Novosana（欧洲）B.V.已共同决定终止此前签署的股权收购意向协议。该协议涉及双方在医药领域的潜在合作，但经协商一致，决定不再推进此项交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2608381416","title":"新华制药：新华制药是全球解热镇痛类药物重要生产企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2608381416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608381416?lang=zh_cn&edition=full","pubTime":"2026-02-03 09:01","pubTimestamp":1770080467,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药02月02日在投资者关系平台上答复投资者关心的问题。投资者提问：据报，截止2月2日，全球流感蔓延爆发，美洲：美国本季累计病例超 2000 万，住院≥27 万，死亡≥1.1 万，近期活动回升，儿童住院率与死亡数显著走高；中美洲、加勒比地区阳性率超 30%。新华制药是全球解热镇痛类药物重要生产企业，目前出口情况并无显著变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300007618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2606144784","title":"新华制药：布洛芬主要用于解热、镇痛、抗炎，是非甾体抗炎常用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2606144784","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606144784?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:12","pubTimestamp":1769515920,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月27日，新华制药在互动平台回答投资者提问时表示，布洛芬主要用于解热、镇痛、抗炎，是非甾体抗炎常用药。公司并未获得印度布洛芬急缺信息。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-01-27/doc-inhiucrr9638599.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-01-27/doc-inhiucrr9638599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2604119094","title":"新华制药（000756）披露部分A股股票期权注销完成公告，1月20日股价上涨1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604119094","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604119094?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:17","pubTimestamp":1768918636,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，新华制药报收于16.53元，较前一交易日上涨1.54%，最新总市值为115.16亿元。该股当日开盘16.28元，最高16.55元，最低16.21元，成交额达3亿元，换手率为3.67%。公司近日发布公告称，因部分激励对象岗位调整、解除合同、退休等原因，山东新华制药股份有限公司注销首次授予的46.20万份股票期权；同时，因预留授予第一个行权期届满且35名激励对象未行权，公司注销59.50万份股票期权。本次注销不影响公司股本结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000039567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159982","000756","399300","BK0164"],"gpt_icon":0},{"id":"2601784600","title":"新华制药调整2021年股权激励计划，行权价格下调并注销部分期权","url":"https://stock-news.laohu8.com/highlight/detail?id=2601784600","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601784600?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:22","pubTimestamp":1767572532,"startTime":"0","endTime":"0","summary":"中访网数据 山东新华制药股份有限公司于2025年12月31日召开董事会会议，审议通过了关于调整其2021年A股股票期权激励计划的多项议案。据此，首次授予的激励对象人数由190名调整为183名，尚未行权的期权数量由736.89万份相应调整至690.69万份。同时，董事会确认该激励计划首次授予的第三个行权期行权条件已经成就，183名激励对象可在该行权期行使其持有的690.69万份股票期权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260105/31913852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2600624030","title":"每周股票复盘：新华制药（000756）获间苯三酚注射液注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2600624030","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600624030?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:18","pubTimestamp":1767377893,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，新华制药报收于15.41元，较上周的15.81元下跌2.53%。本周，新华制药12月29日盘中最高价报15.85元。本周关注点公司公告汇总：新华制药获间苯三酚注射液药品注册证书，拓展新市场。公司公告汇总：间苯三酚注射液2024年公立医疗机构销售额约9亿元。公司公告汇总新华制药近日取得间苯三酚注射液药品注册证书，注册分类为化学药品4类，适用于消化系统、胆道、泌尿系统及妇科痉挛性疼痛治疗，属医保乙类品种。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2595127727","title":"流感疫情持续，防控系统工程再受考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595127727?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172695,"startTime":"0","endTime":"0","summary":"2025年末，全国流感疫情持续处于高流行水平。产业链协同响应，构建多层次供应保障流感防控是一项系统工程，需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫情中，上市药企正通过全产业链布局，搭建从源头预防到终端治疗的健康保障网络。中成药在本轮疫情中表现活跃。公司表示，金振口服液四季度市场需求回暖，正加紧排产满足市场需要。随着该产品儿童流感新适应症的获批，其在儿科领域的应用场景进一步拓宽。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100030908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","600079","BK0086","600557","BK0010","BK0114","BK0060","BK0097","SG9999001069.SGD","603882","002603","BK0042","301207","BK0077","000999","BK0164","688276","BK0188","BK0284","BK0201","BK0074","BK0070","BK0186","BK0096","300937","600566","BK0187","002728","BK0197","BK0028","BK0196","BK0012","BK0239","BK0046","002317","BK0183","BK0236","603858","000623","000756","300244","BK0175","BK0250","BK0185","BK0146"],"gpt_icon":0},{"id":"2595715567","title":"新华制药缬沙坦胶囊获药品注册证书，丰富心血管产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2595715567","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595715567?lang=zh_cn&edition=full","pubTime":"2025-12-30 23:18","pubTimestamp":1767107900,"startTime":"0","endTime":"0","summary":"中访网数据 山东新华制药股份有限公司于近日宣布，其申报的缬沙坦胶囊已获得国家药品监督管理局核发的《药品注册证书》。该药品注册分类为化学药品4类，获批用于治疗轻、中度原发性高血压。缬沙坦胶囊属于《国家基本医疗保险、工伤保险和生育保险药品目录》甲类品种。此次获批标志着新华制药在心脑血管疾病治疗领域的产品管线得到进一步丰富，有望提升公司在该领域的市场竞争力与综合实力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31905046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2595155977","title":"新华制药间苯三酚注射液获药品注册证书，有望开拓新市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2595155977","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595155977?lang=zh_cn&edition=full","pubTime":"2025-12-30 23:18","pubTimestamp":1767107900,"startTime":"0","endTime":"0","summary":"中访网数据 山东新华制药股份有限公司近日宣布，其申报的间苯三酚注射液已获得国家药品监督管理局核准签发的《药品注册证书》。本品主要用于治疗消化系统、胆道功能障碍以及泌尿系统、妇科相关的急性痉挛性疼痛。新华制药表示，此次获得药品注册证书，将有利于公司开拓新的市场领域，提升市场竞争力。同时，公司也提示投资者，药品销售可能受到行业政策、招标采购及市场环境变化等因素影响，存在不确定性风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31905047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2595994786","title":"发力止痛市场，新华制药间苯三酚注射液获批注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2595994786","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595994786?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:41","pubTimestamp":1767001274,"startTime":"0","endTime":"0","summary":"12月29日，新华制药（000756/00719）发布公告，公司的药品“间苯三酚注射液”符合药品注册的有关要求，获批注册。间苯三酚注射液用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉挛性疼痛。根据相关统计数据，2024年中国公立医疗机构间苯三酚注射液销售额约为9亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604513393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2595785549","title":"新华制药：获得缬沙坦胶囊、间苯三酚注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2595785549","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595785549?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:08","pubTimestamp":1766999328,"startTime":"0","endTime":"0","summary":"人民财讯12月29日电，新华制药(000756)12月29日公告，公司近日收到国家药监局核准签发的缬沙坦胶囊、间苯三酚注射液《药品注册证书》。缬沙坦胶囊用于治疗轻、中度原发性高血压。间苯三酚注射液用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉挛性疼痛。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604479435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0164","BK0239","000756"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773699549509,"stockEarnings":[{"period":"1week","weight":-0.0019},{"period":"1month","weight":-0.0191},{"period":"3month","weight":-0.0147},{"period":"6month","weight":-0.0895},{"period":"1year","weight":0.0273},{"period":"ytd","weight":-0.0026}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.068},{"period":"6month","weight":0.0538},{"period":"1year","weight":0.1945},{"period":"ytd","weight":0.0292}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东新华制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1997-08-06","address":"山东省淄博市张店区高新技术产业开发区化工区","registeredCapital":"69668万元","survey":" 山东新华制药股份有限公司的主营业务是开发、制造和销售化学原料药、制剂及化工产品。公司的主要产品是“新华牌”解热镇痛类药物、心脑血管类、抗感染类及中枢神经类等药物。1个项目获山东省2024年度科技进步二等奖。","listedPrice":3.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新华制药,000756,新华制药股票,新华制药股票老虎,新华制药股票老虎国际,新华制药行情,新华制药股票行情,新华制药股价,新华制药股市,新华制药股票价格,新华制药股票交易,新华制药股票购买,新华制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}